Cancer History and GH-Axis Peptides: Why Oncological Screening Comes Before Any Protocol

Growth hormone secretagogues raise IGF-1, a growth factor implicated in tumour biology. This article explains why a personal or family cancer history is one of the most important contraindication screens in physician-led peptide therapy, and how clinicians approach it.

By UAE Peptide Clinic Research Desk

Every responsible peptide consultation begins not with what a protocol might do for you, but with what might make it unsafe. Among the screening questions a prescribing physician asks, few carry more weight than those about cancer: a previous diagnosis, an active malignancy, an unexplained finding awaiting investigation, or a strong family history. This is because a large share of the peptides used in longevity and recovery medicine act on the growth hormone axis, and growth hormone signalling is, by definition, a signal to grow.

Why the GH axis matters in oncological screening

Peptides such as CJC-1295, ipamorelin, sermorelin and tesamorelin work by stimulating the pituitary to release growth hormone. Growth hormone in turn drives the liver to produce insulin-like growth factor 1, or IGF-1. IGF-1 is one of the body's central anabolic messengers: it supports muscle repair, bone density and tissue maintenance. It also promotes cell proliferation and suppresses apoptosis, the programmed cell death that normally clears damaged cells.

Large epidemiological cohorts have associated higher circulating IGF-1 with a modestly increased incidence of certain cancers, notably breast, prostate and colorectal. Research suggests the relationship is one of promotion rather than initiation: IGF-1 does not appear to cause the DNA damage that starts a tumour, but it may provide a more favourable environment for abnormal cells that already exist to survive and expand. The practical implication is that the GH axis should not be stimulated in anyone who may harbour an active or dormant malignancy.

Growth hormone secretagogues do not create cancer. The concern is that they may feed one that is already there, silently, and not yet found.

What a physician actually screens for

Oncological screening in a peptide clinic is a structured conversation supported by bloodwork, not a single yes-or-no question. The areas a clinician will typically explore include:

• Active malignancy of any kind, which is an absolute contraindication to GH-axis peptides and most regenerative peptides.
• Cancer in remission, including how long ago, what type, and whether the patient remains under oncological follow-up. Many clinicians apply a minimum remission interval, often five years, before considering any growth-promoting protocol.
• Unexplained symptoms or findings awaiting investigation, such as a lump, unexplained weight loss, a suspicious skin lesion, or an abnormal scan. Protocols are deferred until these are resolved.
• Family history of hereditary cancer syndromes, which may prompt referral for further screening before proceeding.
• Baseline IGF-1 and, where indicated, tumour markers such as PSA in men over 40, alongside the standard pre-protocol blood panel.

Regenerative peptides such as BPC-157, TB-500 and GHK-Cu warrant similar caution for a related reason. Their proposed benefits rest on promoting angiogenesis, cell migration and tissue growth, which are the very processes tumours co-opt. The preclinical evidence here is limited and mixed, and in the absence of human safety data most physicians treat a cancer history as a reason to withhold them.

Which peptides sit outside the GH axis

A cancer history does not automatically close the door on peptide therapy altogether. Several molecules act through pathways unrelated to growth signalling, and in appropriate cases, with oncologist agreement, they may still be considered. Thymosin alpha-1, for example, is an immunomodulator that has been studied as an adjunct in oncology settings rather than avoided in them. Selank and semax act on neuropeptide and neurotrophic pathways in the central nervous system. NAD+ supports mitochondrial and cellular energy metabolism rather than proliferation, though even here the evidence base is evolving and individual review remains essential.

Clinical nuance: a shared decision, not a blanket rule

The right answer depends on the type of cancer, its hormone sensitivity, the treatment received, the time elapsed, and the patient's goals. A patient ten years clear of a low-grade skin cancer is in a very different position from one eighteen months out from a hormone-receptor-positive breast cancer. Where a patient has a history, a physician-led clinic will usually seek written input from the treating oncologist before proceeding with anything, and will document the rationale for any protocol that is agreed. This is also why DHA-licensed practice matters: the requirement for a genuine physician assessment is exactly what prevents growth-promoting compounds from reaching people who should never receive them.

If you have a cancer history and are exploring peptide therapy as part of your protocol, our clinical team can review your case alongside your oncologist's guidance. Take the 2-minute quiz at /find-my-stack or book a free consultation at /book.